Conveying Quality and Value in Emerging Industries: Star Scientists and the Role of Learning in Biotechnology
28 Pages Posted: 29 Dec 2008 Last revised: 26 Nov 2022
There are 3 versions of this paper
Conveying Quality and Value in Emerging Industries: Star Scientists and the Role of Learning in Biotechnology
Conveying Quality and Value in Emerging Industries: Star Scientists and the Role of Learning in Biotechnology
Date Written: December 2008
Abstract
Managers of private entrepreneurial firms face obstacles in raising capital both in placing a value on a firm and conveying value to investors. These problems are exacerbated when the firm is small, has limited assets (except for human capital) and has yet to have a lead product. In such cases metrics are necessary to convey the value of the firm to investors. Here we explore the importance within the biotechnology industry of the non-financial metrics firms used to convey value during two important initial public offerings (IPO) windows (1989 to 1992 and 1996 to 2000). We also examine whether there was a change over time in the importance of various metrics in determining the value of a biotechnology firm. We find that firms with an affiliated Nobel laureate succeeded in raising the value of their firms by more than $30 million compared to firms without a Nobel laureate during the first period, suggesting that a Nobel laureate served as a powerful signal of firm value. Our results also suggest that the biotechnology regime changed and the Nobel Prize lost its luster as a signal of value in the second period. The importance of several other non-financial metrics changed as well. We conclude that these non-financial metrics of value change in relative importance to potential investors and financial markets as learning occurs and as an industry matures.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
By Ilan Guedj and David S. Scharfstein
-
By Ilan Guedj and David S. Scharfstein
-
Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality
By Sean Nicholson, Patricia M. Danzon, ...
-
Financial Contracting in Biotech Strategic Alliances
By David T. Robinson and Toby Stuart
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
By Patricia M. Danzon, Sean Nicholson, ...